Effects of 1?-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis
- 1 May 1994
- journal article
- clinical trial
- Published by Springer Nature in Calcified Tissue International
- Vol. 54 (5) , 370-376
- https://doi.org/10.1007/bf00305521
Abstract
The effects of 1α-hydroxyvitamin D3 [1α(OH)D3] on bone mineral density, fracture incidence, and bone metabolism were evaluated by a double-blind, placebo-controlled study. Eighty postmenopausal osteoporotic Japanese women (71.9±7.3 years, mean±SD) were randomly assigned to 1 μg of 1α(OH)D3 daily or inactive placebo for 1 year. All patients were given supplemental calcium (300 mg of elemental calcium daily). Lumbar (L2–L4) bone mineral density (BMD) determined by dual energy X-ray absorptiometry increased 0.65% with 1α(OH)D3 treatment and decreased 1.14% with placebo (P=0.037). BMD in both the femoral neck and Ward's triangle did not yield any significant differences between the two groups, whereas trochanter BMD in the 1α(OH)D3-treated group increased 4.20% and decreased 2.37% with placebo (P=0.055). X-ray analysis demonstrated that new vertebral fractures occurred in two patients with 1α(OH)D3 and in seven patients with placebo. The vertebral fracture rate in the treated group was significantly less (75/1000 patient years) than in the control group (277/1000 patient years; P=0.029). Hypercalcemia (12.1 mg/100 ml) occurred in one patient receiving 1α(OH)D3; however, the serum calcium level in this patient promptly decreased to the reference range after cessation of the treatment. There were no significant changes in serum creatinine level in either group. A significant increase in urinary excretion of calcium was found but there was no significant change in urinary excretion of hydroxyproline in the treated group. The serum level of bone-derived alkaline phosphatase activity significantly decreased by−26±26 (mU/ml) after the treatment (P=0.003). These results indicate that 1α(OH)D3 treatment is effective for maintaining trabecular bone mass and prevents further vertebral fractures without any serious adverse effects in postmenopausal osteoporosis.Keywords
This publication has 26 references indexed in Scilit:
- Vitamin D3and Calcium to Prevent Hip Fractures in Elderly WomenNew England Journal of Medicine, 1992
- Osteoporosis and vitamin DJournal of Cellular Biochemistry, 1992
- Treatment of Postmenopausal Osteoporosis with Calcitriol or CalciumNew England Journal of Medicine, 1992
- Effect of Intermittent Oral 1,25(OH)2D3 Therapy on Bone Gla Protein in Dialysis Patients.Endocrinologia Japonica, 1991
- Serum Parathyroid Hormone Concentration Measured by Highly Sensitive Assay in Post-Thyroidectomy Hypocalcemia of Patients with Graves' Disease.Endocrinologia Japonica, 1989
- Postmenopausal Osteoporosis: No Effect of Three Years Treatment with 1,25‐DihydroxycholecalciferolActa Medica Scandinavica, 1987
- TREATMENT OF POST MENOPAUSAL OSTEOPOROSIS. A CONTROLLED THERAPEUTIC TRIAL COMPARING OESTROGEN/GESTAGEN, 1,25‐DIHYDROXY‐VITAMIN D3 AND CALCIUMClinical Endocrinology, 1982
- Effect of 1,25‐dihydroxy ‐ vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosisEuropean Journal of Clinical Investigation, 1981
- A study of immunoreactive calcitonin (CT), adrenocorticotropic hormone (ACTH) and carcinoembryonic antigen (CEA) in lung cancer and other malignanciesCancer, 1981
- Prevention of early postmenopausal bone loss: controlled 2‐year study in 315 normal femalesEuropean Journal of Clinical Investigation, 1980